Summary
Patients with small cell carcinoma of the lung (SCCL) were treated in two multicenter trials with different cytostatic drug regimens including ifosfamide.
In the first randomized study, including 306 patients, alternating chemotherapy with VP 16, ifosfamide, vindesine (VPIV), adriamycin, cisplatinum, vincristine (APO), and cyclophosphamide, methotrexate, CCNU (CMCC) was compared against standard treatment with ACO (adriamycin, cyclophosphamide, vincristine).
It was shown that the alternating therapy resulted in a higher response rate (88% vs 78%) and a longer median survival time (11 months vs 10 months). Regarding toxicity, VPIV was similar to ACO, whereas APO and CMCC had more side-effects, leading to an increase in the number of drop-outs.
In the second randomized study 144 patients were treated either with ifosfamide/VP 16 (IVP) or with cisplatinum/VP 16 (PVP). In the case of no further response, no change, or progression the induction therapy was changed to ACO. Interim analyses show that both regimens have similar therapeutic effects; but higher toxicity was observed in patients treated withcis-platinum/VP 16 than in patients treated with ifosfamide/VP 16.
According to the response rate in patients treated with ACO after first-line therapy there was less cross-resistance of IVP than of PVP to ACO.
Similar content being viewed by others
References
Cohen MH, Ihde DC, Bunn PA et al (1979) Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 63: 163–170
Dombernowsky P, Hansen HH, Sörenson S, Österlind K (1979) Sequential versus non-sequential combination chemotherapy using 6 drugs in advanced small cell carcinoma: a comparative trial including 146 patients. Proc Am Assoc Cancer Res 20: 277
Harms V, Havemann K, Gropp C et al (1983) A randomized multicenter trial comparing sequential versus alternating polychemotherapy in small cell lung cancer. XIIIth Int Congress on Chemotherapy, Vienna, Proceedings, vol 16: 248/10
Mehta C, Vogl SE (1982) Cyclic non-cross-resistant combination chemotherapy for small cell lung cancer in remission, 50% prolongation of remission duration without prolongation of survival and with enhanced toxicity. Proc Am Soc Cancer Res, Abstr
Sierocki JS, Hilaris BS, Hopfan S, et al (1980) Small cell carcinoma of the lung: experience with a six-drug regimen. Cancer 45: 417–422
Sikie BI, Daliels JR, Chak L, et al (1981) POCC versus POCC-VAM therapy for small cell lung cancer. In: Prestayko AW, eds, Nitrosoureas: Current status and new developments. Academic Press, New York, pp 221–231
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Havemann, K., Gropp, C., Klapsing, J. et al. Two randomized trials for alternating polychemotherapy of small cell lung cancer. Cancer Chemother. Pharmacol. 18 (Suppl 2), S40–S44 (1986). https://doi.org/10.1007/BF00647450
Issue Date:
DOI: https://doi.org/10.1007/BF00647450